1. Co-delivery of vitamin and amino acid within MOFs for oxidative stress-based tumor gas therapy.
- Author
-
Yan X, Jing P, Zhuang Z, Zhang J, Chen H, Xia T, and Jiang K
- Subjects
- Animals, Mice, Humans, Tumor Microenvironment drug effects, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Antineoplastic Agents administration & dosage, Particle Size, Nitric Oxide administration & dosage, Nitric Oxide chemistry, Nitric Oxide metabolism, Surface Properties, Hydrogen Peroxide metabolism, Hydrogen Peroxide chemistry, Cell Proliferation drug effects, Zeolites chemistry, Cell Line, Tumor, Gases chemistry, Drug Screening Assays, Antitumor, Cell Survival drug effects, Imidazoles chemistry, Imidazoles pharmacology, Oxidative Stress drug effects, Metal-Organic Frameworks chemistry, Metal-Organic Frameworks pharmacology, Arginine chemistry
- Abstract
As an alternative to chemotherapy, emerging gas therapy is considered a "green" treatment due to its minimal side effects. However, even typical gas molecules like nitric oxide (NO) face challenges such as a very short half-life (1.5-6 min), poor targeting, and limited therapeutic effects. This study employs a one-pot method to simultaneously encapsulate the NO donor L-arginine (L-Arg) and the H
2 O2 precursor Vitamin K3 (VK3) into the pores of zeolitic imidazolate framework-8 (ZIF-8), achieving their co-delivery to tumor sites to address these issues. Furthermore, ZIF-8 is functionalized with hyaluronic acid (HA) to impart active targeting properties to tumor tissues. In the acidic tumor microenvironment, pH-sensitive ZIF-8 degrades, releasing VK3 and L-Arg. Under the action of the NAD(P)H quinone oxidoreductase-1 (NQO1) enzyme, VK3 generates H2 O2 , increasing oxidative stress levels in the tumor microenvironment, and reacts with L-Arg to produce NO, thereby achieving tumor oxidative stress-based gas therapy. Both in vitro and in vivo experiments showed good tumor treatment effects, with a tumor inhibition rate of up to 90.5 % and minimal impact on normal tissues and organs. This approach demonstrates efficient loading, controlled release, and significant anti-tumor performance, offering new insights into gas and reactive oxygen species (ROS) synergistic therapy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2025
- Full Text
- View/download PDF